论文部分内容阅读
目的系统评价阿奇霉素治疗支气管哮喘疗效及安全性。方法选择2016年4月~2017年4月于我院就诊的支气管哮喘患者90例,按进入医院的编号分为观察组和对照组,每组45例。对照组给予普通治疗,观察组采用阿奇霉素治疗,对两组患者的疗效与不良反应进行对比。结果观察组总有效率为95.56%,对照组为62.22%,差异有统计学意义(P<0.05)。观察组不良反应发生率为6.67%(口干2例、恶心1例),对照组为40.00%(口干4例、恶心6例、心悸3例、失眠2例、手指震颤3例),差异有统计学意义(P<0.05)。结论在治疗支气管哮喘的过程,应用阿奇霉素治疗有助于极大的增强疗效,不良反应的发生率低,可以在临床上进行大力的应用与推广。
Objective To evaluate the efficacy and safety of azithromycin in the treatment of bronchial asthma. Methods 90 patients with bronchial asthma admitted to our hospital from April 2016 to April 2017 were divided into the observation group and the control group according to the numbers entering the hospital, with 45 cases in each group. The control group was given general treatment. The observation group was treated with azithromycin. The curative effect and adverse reaction of the two groups were compared. Results The total effective rate was 95.56% in the observation group and 62.22% in the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 6.67% (2 cases of dry mouth, 1 case of nausea) and 40.00% of the control group (4 cases of dry mouth, 6 cases of nausea, 3 cases of palpitation, 2 cases of insomnia and 3 cases of finger tremor) There was statistical significance (P <0.05). Conclusion In the treatment of bronchial asthma, the application of azithromycin can greatly enhance the efficacy of treatment, the incidence of adverse reactions is low, and can be clinically applied and promoted.